|
HUMALOG
Product Brand Name: Lantus, Humalog, Lispro-PFC, Humalog
Pen, Novolog, Novolog FlexPen ®
|
 |
|
| |
 |
Reviews |
|
IEEE Trans Biomed Eng. 2005 Jan;52(1):3-12.
Insulin kinetics in type-I diabetes: continuous and
bolus delivery of rapid acting insulin.
Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber
TR, Hovorka R.
Department of Paediatrics, University of Cambridge, Cambridge, CB2 2QQ,
UK. mew37@medschl.cam.ac.uk We investigated insulin lispro kinetics with
bolus and continuous subcutaneous insulin infusion (CSII) modes of insulin
delivery. Seven subjects with type-1 diabetes treated by CSII with insulin
lispro have been studied during prandial and postprandial conditions over
12 hours. Eleven alternative models of insulin kinetics have been proposed
implementing a number of putative characteristics. We assessed 1) the
effect of insulin delivery mode, i.e., bolus or basal, on the insulin
absorption rate, the effects of 2) insulin association state and 3) insulin
dose on the rate of insulin absorption, 4) the remote insulin effect on
its volume of distribution, 5) the effect of insulin dose on insulin disappearance,
6) the presence of insulin degradation at the injection site, and finally
7) the existence of two pathways, fast and slow, of insulin absorption.
An iterative two-stage parameter estimation technique was used. Models
were validated through assessing physiological feasibility of parameter
estimates, posterior identifiability, and distribution of residuals. Based
on the principle of parsimony, best model to fit our data combined the
slow and fast absorption channels and included local insulin degradation.
The model estimated that 67(53-82)% [mean (interquartile range)] of delivered
insulin passed through the slow absorption channel [absorption rate 0.011(0.004-0.029)
min(-1)] with the remaining 33% passed through the fast channel [absorption
rate 0.021(0.011-0.040) min(-1)]. Local degradation rate was described
as a saturable process with Michaelis-Menten characteristics [VMAX = 1.93(0.62
- 6.03) mU min(-1), KM = 62.6(62.6 - 62.6) mU]. Models representing the
dependence of insulin absorption rate on insulin disappearance and the
remote insulin effect on its volume of distribution could not be validated
suggesting that these effects are not present or cannot be detected during
physiological conditions.
|
Value Health. 2004 Jul-Aug;7(4):442-54.
Patient
preference and willingness-to-pay for Humalog Mix25 relative to Humulin
30/70: a multicountry application of a discrete choice experiment.
Aristides M, Weston AR, FitzGerald P, Le Reun C, Maniadakis
N.
M-TAG Limited, London, England, UK. maristides@m-tag.net.
OBJECTIVES: To assess preference and willingness-to-pay (WTP) for the
insulin mixture Humalog Mix25 relative to Humulin 30/70, from the patients'
perspective, the relative importance of individual treatment attributes
was also determined. Differences among five European countries were investigated.
METHODS: Two hundred and ninety patients with type 2 diabetes were recruited
from five European countries. Of these, 235 were suitable for inclusion
in the analysis. Their mean age was 51.3 years and, on average, patients
had had diabetes for 11 years. A discrete-choice conjoint analysis was
conducted using face-to-face interviews. Treatment attributes, such as
timing of injections around meals, 2-hour postprandial control, effect
of prandial dosing, frequency of nocturnal hypoglycemia, and cost, and
levels were derived after a systematic review of all published comparative
clinical trial data. Meta-analyses were undertaken where appropriate.
RESULTS: Ninety percent (95% CI 86-93%) of patients would choose Humalog
Mix25 over Humulin 30/70, at the same cost. On average, European subjects
were willing to pay 111 euros per month more for Humalog Mix25 (95% CI
86.71-156.91 euros). The primary driver was the reduced risk of nocturnal
hypoglycemic events, contributing 49% of WTP. The convenience of dosing
immediately before the meal contributed 37%. Preference results were similar
in all five countries, although WTP and sensitivity to increasing cost
both varied. CONCLUSIONS: Patients in all countries showed a preference
and WTP for Humalog Mix25 over Humulin 30/70. The main drivers of patient
WTP may be of interest to pharmaceutical prescribers, manufacturers, and
reimbursement agencies.
|
| |
|
Drug information |
|
Generic Name: humalog
Product Brand Name: Lantus, Humalog, Lispro-PFC, Humalog
Pen, Novolog, Novolog FlexPen ®
1. Humalog (Injection) is used for the Treatment
Treats diabetes mellitus (sugar diabetes). Insulin is a hormone that
helps get sugar from the blood to the muscles, where it is used for
energy.
2. When To Not Use Humalog (Injection)
Talk with your doctor before using this medicine if you have had an
allergic reaction to any type of insulin.
3. How Should You Use Humalog (Injection)
Injectable
- Your doctor will prescribe your exact dose and tell you how often
it should be given. This medicine is given as a shot under your skin.Do
not change the brand or dose of your insulin unless your doctor tells
you to.
- You will be taught how to give your medicine at home. Make sure
you understand all instructions before giving yourself an injection.
Do not use more medicine or use it more often than your doctor tells
you.
- This medicine comes with patient instructions. Read and follow
these instructions carefully. Ask your doctor or pharmacist if you
have any questions.
- You will be shown the body areas where this shot can be given.
Use a different body area each time you give yourself a shot. Keep
track of where you give each shot to make sure you rotate body areas.
- Use only syringes that are made specially for giving insulin injections.
Always use the same brand and type of syringe. Avoid switching insulin
brands as much as possible. Some types of insulin must be used with
a certain type of syringe. Ask your pharmacist if you are not sure
which one to use.Use a new needle and syringe each time you inject
your medicine.
- If you are using a reusable syringe, you must sterilize it before
each dose. Follow the sterilizing directions that came with your syringes.
- Do not mix one kind of insulin with another kind or with water,
unless your doctor has told you to. Never mix Lantus® (insulin
glargine) with any other insulin or with water.
- Carefully follow your doctor's instructions about any special diet.
- Your doctor may suggest that you follow an exercise program. You
may also be taught to check your own blood sugar levels at home. Diet,
exercise, medicine, and checking your blood sugar are important to
control your diabetes. If a dose is missed:
Call your doctor or pharmacist for instructions.
4. Proper Humalog (Injection) Storage
Store Humalog (Injection) at room temperature away from sunlight and
moisture. Keep Humalog (Injection) and all medications out of the reach
of children.
5. What To Avoid While Using Humalog (Injection)
Ask your doctor or pharmacist before using any other medicine, including
over-the-counter medicines, vitamins, and herbal products.
6. Humalog (Injection) Warnings
- Tell your doctor if you are pregnant or are planning to become
pregnant.
- You may have low blood sugar while you are using insulin, especially
if you miss a meal, exercise for a long time, or drink alcohol. Symptoms
of low blood sugar include sweating, feeling very hungry, a fast heartbeat,
vision changes, drowsiness, confusion, persistent headache, chills,
or vomiting.
- Ask your doctor what to do if you have low blood sugar. You will
need to control it quickly. Teach your friends, co-workers, or family
members what they can do to help you in case you have low blood sugar.
- The dose of insulin that you need may change slightly with changes
in your diet or activity. Your dose needs may also change while you
are ill, pregnant, traveling, taking a new medicine, or exercising
more than usual. Follow your doctor's instructions about making any
changes in your insulin dose.
7. Humalog (Injection) Side Effects
Call your doctor right away if you notice any of these side effects:
- Allergic reaction: Itching or hives, swelling in your face or hands,
swelling or tingling in your mouth or throat, chest tightness, trouble
breathing.
- Seizures (convulsions).
- Fainting. If you notice these less serious side effects, talk with
your doctor.
- Red, itchy, or swollen skin where the shot is given.
Caution! Before starting
to take this medicine, it is vital that you should consult your doctor!
Do not use it on your own initiative, without medical advice. |
| |
|
Order now ! |
|
HUMALOG (Antidiabetic agents)
|
|
Dosage |
Packing |
Price |
Pay now |
(3 ml) 100 IU/ml, 3,5 mg/ml 5 amp. |
USD 0.00 |
|
|
|
| |
|  
|
|
